Peptide Approaches to Glaucoma Treatment
Glaucoma and Eye Peptides
100M+ affected worldwide
Glaucoma affects over 100 million people globally, yet every approved treatment targets intraocular pressure alone. Peptide-based strategies are emerging to protect retinal ganglion cells directly.
Cen et al., PNAS, 2021
Cen et al., PNAS, 2021
View as imageEvery drug currently approved for glaucoma does the same thing: lower intraocular pressure (IOP). IOP reduction slows disease progression in most patients, but it does not stop it. Approximately 10-15% of glaucoma patients have normal IOP at diagnosis, and many patients continue losing vision despite achieving target pressures. The missing piece is neuroprotection: directly protecting the retinal ganglion cells (RGCs) whose death causes irreversible vision loss. No neuroprotective agent has been approved for glaucoma, but several peptide-based approaches have shown promising preclinical results. These range from alpha-crystallin-derived peptides (peptains) that inhibit RGC apoptosis, to neuropeptide Y receptor activation that preserves inner retinal integrity, to the unexpected finding that GLP-1 receptor agonists prescribed for diabetes and obesity may reduce glaucoma risk.[1] This article surveys the peptide research landscape for glaucoma, covering both neuroprotective and pressure-lowering strategies. For specific coverage of endothelin's role in glaucoma and neuroprotective peptides for retinal ganglion cells, see our dedicated articles.
Key Takeaways
- Peptain-1, derived from alpha-crystallin, protected retinal ganglion cells when administered systemically in two rodent glaucoma models, making it the first peptide to show neuroprotective efficacy through non-ocular delivery (Stankowska et al., Cell Death Discov, 2019)
- Neuropeptide Y receptor activation preserved inner retinal integrity through PI3K/Akt signaling in a mouse glaucoma model, with truncated NPY(3-36) showing selective neuroprotection without vasoconstriction (Palanivel et al., PNAS Nexus, 2024)
- Semaglutide protected retinal ganglion cells against mitochondrial dysfunction-induced degeneration by improving mitochondrial membrane potential and reducing neuroinflammation (Mouhammad et al., IOVS, 2026)
- Tirzepatide use was associated with a 22% reduced risk of primary open-angle glaucoma and ocular hypertension compared to GLP-1 agonists alone in a cohort study of 202,621 patients (Hong et al., Am J Ophthalmol, 2026)
- A small peptide antagonist of the Fas receptor inhibited neuroinflammation and prevented both RGC death and axon degeneration in chronic glaucoma models (Krishnan et al., J Neuroinflammation, 2019)
- The mitochondria-targeted antioxidant peptide SS-31 reduced RGC loss by 30% in a rat experimental glaucoma model through preservation of mitochondrial function (Wu et al., Acta Biochim Biophys Sin, 2019)
Why Glaucoma Needs More Than Pressure Reduction
Glaucoma is a group of optic neuropathies characterized by progressive degeneration of retinal ganglion cells and their axons, which form the optic nerve. The primary modifiable risk factor is elevated intraocular pressure, and every approved treatment, from prostaglandin analog eye drops to laser trabeculoplasty to surgical shunts, works by reducing IOP.
But IOP reduction has clear limitations. Normal-tension glaucoma (IOP below 21 mmHg) accounts for roughly 30-40% of open-angle glaucoma cases in some populations. Progression continues in 40-60% of patients even after IOP is reduced to target levels. And once retinal ganglion cells die, they do not regenerate. The optic nerve, unlike peripheral nerves, cannot repair itself.
This creates the rationale for neuroprotection: interventions that protect RGCs from death independent of IOP. Several neuroprotective strategies have been tested in clinical trials (memantine, brimonidine, neurotrophic factors), but none has achieved regulatory approval for glaucoma specifically. The memantine failure was particularly instructive: two large phase 3 trials (2008) found no significant benefit over placebo, despite strong animal model data. The trial design, patient selection, and endpoint measurement (visual field) were all questioned, but the result cooled pharmaceutical investment in glaucoma neuroprotection for years.
Peptide-based approaches offer several potential advantages: they can target specific receptors and signaling pathways with high selectivity, they can be engineered for different delivery routes (intravitreal, systemic, topical), and some endogenous neuropeptides already play established protective roles in retinal tissue. The diversity of peptide strategies now under investigation reflects the multiple pathways through which RGCs die in glaucoma: apoptosis, neuroinflammation, mitochondrial dysfunction, excitotoxicity, and vascular insufficiency.
Peptain-1: Alpha-Crystallin Peptide Neuroprotection
Alpha-crystallins are small heat shock proteins expressed at high levels in the lens but also present in the retina, where they serve chaperone and anti-apoptotic functions. Stankowska et al. (2019) identified peptain-1, a short peptide derived from the alpha-crystallin domain that retains both chaperone activity and anti-apoptotic properties.[2]
In two rodent models of glaucoma (microbead-induced ocular hypertension in mice and Morrison's model of IOP elevation in rats), systemic intraperitoneal injection of peptain-1 reduced RGC death. The peptide also protected cultured rat primary RGCs against hypoxia-induced death. The finding that systemic delivery worked was particularly notable: it meant the peptide crossed biological barriers to reach the retina after peripheral injection, avoiding the need for intravitreal injections that carry infection risk and patient compliance issues.
Subsequent work showed that conjugating peptain-1 to a cell-penetrating peptide (CPP-P1) enhanced its retinal delivery and neuroprotective effects. In silicone oil-induced ocular hypertension models, CPP-P1 attenuated RGC loss by approximately 37%, preserved retinal function, and reduced axonal degeneration. The mechanism involves activation of CREB signaling and synaptogenesis pathways, with a 1.6-fold increase in Creb1 mRNA expression in treated retinas.
Neuropeptide Y: Inner Retinal Preservation
Neuropeptide Y (NPY) is a 36-amino-acid endogenous peptide with established neuroprotective properties in the central nervous system. Palanivel et al. (2024) demonstrated that NPY receptor activation specifically preserved inner retinal integrity in a mouse model of glaucoma (microbead-induced IOP elevation).[3]
The mechanism operates through the PI3K/Akt survival signaling pathway, one of the key anti-apoptotic cascades in neurons. NPY receptor activation increased phosphorylation of Akt in retinal neurons, promoting cell survival under conditions of elevated IOP stress.
However, full-length NPY activates multiple receptor subtypes (Y1 through Y5), and Y1 receptor activation causes vasoconstriction. This is a potentially harmful effect in glaucoma, where optic nerve head blood flow is already compromised and reduced perfusion contributes to RGC death independently of IOP. Palanivel et al. (2025) addressed this by testing the truncated form NPY(3-36), which selectively activates Y2 and Y5 receptors while avoiding Y1-mediated vasoconstriction.[4] This selective receptor modulation dissociates the neuroprotective effects from the vascular effects, potentially making truncated NPY a safer candidate for glaucoma treatment.
GLP-1 Receptor Agonists: The Unexpected Glaucoma Connection
Perhaps the most surprising development in peptide-based glaucoma research involves GLP-1 receptor agonists, drugs originally developed for type 2 diabetes and obesity. Multiple lines of evidence now suggest these peptides may protect against glaucoma.
Hong et al. (2026) conducted a retrospective cohort study of 202,621 patients and found that tirzepatide (a dual GLP-1/GIP agonist) was associated with a 22% reduced risk of primary open-angle glaucoma and ocular hypertension compared to GLP-1 receptor agonists alone.[5] This is observational data and cannot prove causation, but the effect size was statistically robust after adjusting for multiple confounders.
Mouhammad et al. (2026) provided mechanistic support. In a rotenone-induced model of mitochondrial dysfunction (which mimics one of the proposed pathways of RGC death in glaucoma), semaglutide protected retinal ganglion cells by improving mitochondrial membrane potential and reducing markers of neuroinflammation.[6] An earlier study by the same group (2025) showed that systemic semaglutide provided vasoprotective and anti-neuroinflammatory effects in the retina.[7]
Xie et al. (2025) reviewed the broader evidence for GLP-1 receptor agonists in ocular therapeutics, noting that the anti-inflammatory, antioxidant, and neuroprotective properties of these drugs may benefit multiple eye diseases beyond just glaucoma, including diabetic retinopathy and age-related macular degeneration.[8] Gong et al. (2026) provided a comprehensive review of mechanisms by which GLP-1RAs may influence ocular disease, including direct neuroprotection through GLP-1 receptors expressed on retinal neurons, reduction of neuroinflammatory mediators (TNF-alpha, IL-6), and improvement of retinal blood flow through endothelial nitric oxide synthase activation.[9]
The GLP-1 agonist data is particularly compelling because, unlike every other peptide strategy discussed here, GLP-1 agonists are already FDA-approved and prescribed to millions of patients. If ongoing observational and mechanistic studies continue to support a protective effect, retrospective analysis of existing patient databases and secondary endpoints in ongoing metabolic trials could provide large-scale evidence much faster than de novo glaucoma drug development typically allows. This represents a fundamentally different path to clinical translation than the traditional preclinical-to-clinical pipeline that other glaucoma neuroprotection candidates must follow.
Other Peptide Strategies
Fas Receptor Peptide Antagonist
Krishnan et al. (2019) developed a small peptide antagonist of the Fas receptor, a key mediator of apoptosis and neuroinflammation in glaucoma. In a chronic ocular hypertension model, this peptide inhibited microglia activation, reduced inflammatory cytokine production, and prevented both RGC death and axon degeneration. The Fas/FasL signaling pathway is particularly relevant to glaucoma because it mediates not just direct apoptosis but also the neuroinflammatory cascade that amplifies RGC damage beyond what IOP elevation alone would cause.[10]
Mitochondria-Targeted Peptide SS-31
Mitochondrial dysfunction is increasingly recognized as a contributor to RGC death in glaucoma. Wu et al. (2019) tested SS-31 (Szeto-Schiller peptide 31, also known as elamipretide), a mitochondria-targeted antioxidant peptide, in a rat glaucoma model. Intraperitoneal injection of SS-31 reduced RGC loss by approximately 30%, with the mechanism involving preservation of mitochondrial membrane potential and reduction of oxidative stress markers in the retina.[11]
GHRH Agonist Enhancement
Cen et al. (2021) found that an agonist of growth hormone-releasing hormone (GHRH) enhanced RGC protection in glaucoma models. Published in PNAS, the study demonstrated that GHRH agonist treatment increased RGC survival through mechanisms involving neurotrophic factor signaling, suggesting that growth factor pathway modulation represents another peptide-based avenue for glaucoma neuroprotection.[1]
Collagen Mimetic Peptide
Ribeiro et al. (2022) tested intraocular delivery of a collagen mimetic peptide that repairs retinal ganglion cell axons. This approach targets the structural damage rather than preventing cell death per se, promoting axonal regrowth in models of optic nerve injury. While still preclinical, this represents a regenerative rather than purely protective strategy.[12]
Amyloid-Beta Connection
Ohashi et al. (2025) found correlations between amyloid-beta peptide levels in aqueous humor and retinal nerve fiber layer thickness in glaucoma patients, suggesting that the same neurotoxic peptide fragments implicated in Alzheimer's disease may also contribute to RGC degeneration. This finding opens potential therapeutic connections between anti-amyloid peptide strategies and glaucoma treatment, and it adds to the evidence that glaucoma may share pathological mechanisms with other neurodegenerative diseases, not just in the central nervous system broadly but at the molecular peptide level.[13]
The Endothelin Side
Endothelin-1, a potent vasoconstrictor peptide, is elevated in the aqueous humor and plasma of glaucoma patients. It reduces optic nerve head blood flow and has direct neurotoxic effects on retinal ganglion cells. Lau et al. (2006) demonstrated that acute endothelin-1 delivery causes RGC loss in animal models.[14] Rosenthal et al. (2011) reviewed the evidence for endothelin antagonism as a therapeutic principle in glaucoma, noting that blocking endothelin receptors could simultaneously improve optic nerve blood flow and reduce direct neurotoxicity. This dual mechanism makes endothelin antagonism one of the few peptide-related strategies that addresses both vascular and neuronal components of glaucoma pathology.[15] For the full evidence on this pathway, see our endothelin and glaucoma article.
Limitations and Gaps
All neuroprotective peptide data is preclinical. No peptide neuroprotective agent has entered phase 3 clinical trials for glaucoma. The gap between rodent models and human glaucoma is substantial: human disease progresses over years to decades, while rodent models operate over weeks to months.
The GLP-1 agonist evidence is observational. The tirzepatide-glaucoma association from Hong et al. is from a retrospective cohort, not a randomized trial. Confounding by indication (patients prescribed GLP-1 agonists differ systematically from those who are not) is a concern despite statistical adjustment. Weight loss itself reduces IOP modestly, so some of the observed benefit may be metabolic rather than directly neuroprotective. A randomized trial of GLP-1 agonists specifically for glaucoma prevention has not been conducted.
Delivery remains a major challenge. Peptides generally have poor bioavailability and short half-lives. Reaching the retina at therapeutic concentrations through systemic delivery (as peptain-1 does) or sustained intravitreal delivery (as collagen mimetic peptide requires) presents distinct engineering challenges.
Translation has been slow. The gap between promising preclinical results and clinical approval in glaucoma is historically large. Several non-peptide neuroprotective agents (including memantine, a small molecule) failed in phase 3 despite strong preclinical evidence. The slow, variable progression of human glaucoma makes it difficult to design trials with endpoints that can be measured in a commercially viable timeframe.
Animal models do not fully replicate human disease. Most preclinical glaucoma models involve acute or subacute IOP elevation over weeks. Human open-angle glaucoma typically develops over decades. The mechanisms of RGC death may differ between acute pressure insults (which dominate rodent models) and the chronic, low-grade stress that characterizes the human disease.
The Bottom Line
Peptide-based glaucoma research spans multiple strategies: alpha-crystallin-derived peptains that inhibit RGC apoptosis through systemic delivery, neuropeptide Y receptor activation that preserves inner retinal integrity through PI3K/Akt signaling, GLP-1 receptor agonists that unexpectedly reduce glaucoma risk through anti-inflammatory and mitochondrial protective mechanisms, and endothelin antagonism that improves optic nerve blood flow. All neuroprotective peptide approaches remain preclinical, but the GLP-1 agonist data from large retrospective cohorts adds a new dimension by showing that widely prescribed peptide drugs may already be protecting against glaucoma in millions of patients.